Analyst Upgrades – Acorda Therapeutics (NASDAQ:ACOR) Stock Gets Upgraded By Goldman Sachs Group from Sell to Neutral

Analyst Ratings For Acorda Therapeutics (NASDAQ:ACOR)

Story continues below

Today, Acorda Therapeutics (NASDAQ:ACOR) stock received an upgrade by Goldman Sachs Group from Sell to Neutral.

Some recent analyst ratings include

  • 2/7/2018-Goldman Sachs Group Upgrade from a “Sell ” rating to a ” Neutral” rating.
  • 1/17/2018-HC Wainwright Reiterated Rating of Buy .
  • 1/9/2018-JPMorgan Chase & Co. Reiterated Rating of Hold.
  • 11/28/2017-Piper Jaffray Companies Reiterated Rating of Neutral.
  • 11/17/2017-Cowen Reiterated Rating of Buy.


  • On 1/19/2018 David Lawrence, Insider, sold 31,000 with an average share price of $27.58 per share and the total transaction amounting to $854,980.00.
  • On 12/1/2017 Burkhard Blank, Insider, sold 11,050 with an average share price of $20.53 per share and the total transaction amounting to $226,856.50.
  • On 10/9/2017 David Lawrence, Insider, sold 250 with an average share price of $25.40 per share and the total transaction amounting to $6,350.00.
  • On 8/29/2017 Scopia Capital Management Lp, Major Shareholder, bought 766,201 with an average share price of $19.23 per share and the total transaction amounting to $14,734,045.23.
  • On 8/1/2017 Barry E Greene, Director, sold 10,000 with an average share price of $21.57 per share and the total transaction amounting to $215,700.00.
  • On 7/31/2017 Lorin Randall, Director, sold 10,000 with an average share price of $21.66 per share and the total transaction amounting to $216,600.00.
  • On 6/16/2017 Ron Cohen, Insider, bought 20,000 with an average share price of $16.95 per share and the total transaction amounting to $339,000.00.

Recent Trading Activity for Acorda Therapeutics (NASDAQ:ACOR)
Shares of Acorda Therapeutics closed the previous trading session at 25.40 up +0.50 2.01% with 25.25 shares trading hands.

An ad to help with our costs